Parkinsonian Syndrome Clinical Trial
Official title:
Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms
The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear from a clinical standpoint.
- Subjects will be referred to the Institute for Neurodegenerative Disorders (IND) by
practicing general neurologists with genuine uncertainty regarding the subject's
diagnosis.
- Subjects with suspected PD or PS will be evaluated clinically and with DAT imaging,
using b-CIT and SPECT. The DAT imaging procedure will take place over two days:
- On the first day participants are injected with [123I]ß CIT, an investigational
radioactive material that localizes in the brain. Study participants will also have a
thorough neurologic examination and standard neuropsychological testing, including
testing of memory, concentration, abstraction and visual spatial functions.
- Twenty-four hours later study participants return to the Institute for
Neurodegenerative Disorders where an investigational scanning procedure will be used to
obtain SPECT (single photon emission computed tomography) images of the brain.
- Subjects will be asked to return within 3 months following the imaging study to have a
repeat neurological examination by the two study neurologists at IND.
- Subjects will be asked to return at about 6 months and possibly again at one year
following the imaging study for a final clinical evaluation by one of the study
neurologists at IND.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00132626 -
Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
|
Phase 2 | |
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
Completed |
NCT00096876 -
A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
|
||
Completed |
NCT00117195 -
A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
|
N/A | |
Completed |
NCT00117819 -
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
|
Phase 2 | |
Completed |
NCT04193527 -
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
|
Phase 3 | |
Completed |
NCT04974034 -
Movement Disorders Analysis Using a Deep Learning Approach
|
||
Completed |
NCT00354003 -
The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
|
||
Completed |
NCT04925622 -
Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
|
||
Completed |
NCT00315250 -
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
|
Phase 2 | |
Completed |
NCT00273351 -
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
|
Phase 2 | |
Completed |
NCT00129181 -
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease
|
N/A | |
Completed |
NCT00096720 -
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
|
Phase 2 | |
Recruiting |
NCT05110547 -
Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions
|